Extrapyramidal side-effects and prediction of neuroleptic treatment response

  • W. W. Fleischhacker
Conference paper


When antipsychotics were introduced into clinical psychiatry in the 1950’s extrapyramidal motor side effects (EPS) were felt to be an integral part of their profile of action. The propensity to induce EPS in animal models was an important part of the screening procedures in the development of antipsychotics. The term “neuroleptic” that was coined to characterize this new class of drugs had to do with their impact on motor functions. It wasn’t until the development of clozapine that psychopharmacologists realized that antipsychotic efficacy is not necessarily linked to EPS.


Tardive Dyskinesia Brief Psychiatric Rate Scale Acute Dystonia Antipsychotic Efficacy Bioi Psychiatry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bishop MP, Gallant DM, Sykes TF (1965) Extrapyramidal side effects and therapeutic response. Arch Gen Psychiatry 13:155–162.PubMedCrossRefGoogle Scholar
  2. Buchanan RW, Kirkpatrick B, Summerfelt A, Hanlon TE, Levine J, Carpenter Jr WT (1992) Clinical predictors of relapse following neuroleptic withdrawal. Biol Psychiatry 32:72–78.PubMedCrossRefGoogle Scholar
  3. Chakos MH, Mayerhoff DI, Loebel AD, Alvier JM, Lieberman JA (1992) Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 28:81–86.PubMedGoogle Scholar
  4. Cohen BM, Keck PE, Satlin A, Cole JO (1991) Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 29:1215–1219.PubMedCrossRefGoogle Scholar
  5. Fleischhacker WW, Meise U, Günther V, Kurz M (1994) Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 89[Suppl 382]: 11–15.Google Scholar
  6. Goldman D (1961) Parkinsonism and related phenomena from administration of drugs: their production and control under clinical conditions and possible relation to therapeutic effect. Rev Can Biol 20:549–560.PubMedGoogle Scholar
  7. Hogan TP, Awad AG (1992) Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 22:347–352.PubMedCrossRefGoogle Scholar
  8. Hollister LE, Chaffey EM, Klett CJ (1960) Abnormal symptoms, signs and laboratory tests during treatment with phenothiazine derivatives. Clin Pharmacol Ther 1:284–293.PubMedGoogle Scholar
  9. Levinson DF, Simpson GM, Singh H, Yadalam K, Jain A, Stephanos J, Silver P (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 47:761–768.PubMedCrossRefGoogle Scholar
  10. Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J (1987) Prediction of relapse in schizophrenia. Arch Gen Psychiatry 44:597–603.PubMedCrossRefGoogle Scholar
  11. McEvoy JP, Schooler NR, Wilson WH (1991) Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacol Bull 27:97–101.PubMedGoogle Scholar
  12. McEvoy JP, Hogarty GE, Steingard S (1991a) Optimal dose of neuroleptic in acute schizophrenia. Arch Gen Psychiatry 48:739–745.PubMedCrossRefGoogle Scholar
  13. Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31:67–72.PubMedCrossRefGoogle Scholar
  14. Van Putten T, May PRA, Marder SR (1984) Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 41:1036–1039.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1994

Authors and Affiliations

  • W. W. Fleischhacker
    • 1
  1. 1.Department of Biological PsychiatryInnsbruck University ClinicsInnsbruckAustria

Personalised recommendations